Literature DB >> 18524600

Citral derived amides as potent bacterial NorA efflux pump inhibitors.

Niranjan Thota1, Surrinder Koul, Mallepally V Reddy, Payare L Sangwan, Inshad A Khan, Ashwani Kumar, Alsaba F Raja, Samar S Andotra, Ghulam N Qazi.   

Abstract

Monoterpene citral and citronellal have been used as starting material for the preparation of 5,9-dimethyl-deca-2,4,8-trienoic acid amides and 9-formyl-5-methyl-deca-2,4,8-trienoic acid amides. The amides on bioevaluation as efflux pump inhibitors (EPIs) against Staphylococcus aureus 1199 and NorA overexpressing S. aureus 1199B bacteria resulted in the identification of several of these as potent EPIs. Many of these amides have been shown to possess potency higher or equivalent to known EPIs such as reserpine, verapamil, carsonic acid, and piperine. In this communication, we report a convenient synthesis of alkenyl amides, their bioevaluation and identification as efflux pump inhibitors against S. aureus.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18524600     DOI: 10.1016/j.bmc.2008.05.030

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

1.  Advances in the structural studies of antibiotic potentiators against Escherichia coli.

Authors:  Gifty A Blankson; Ajit K Parhi; Malvika Kaul; Daniel S Pilch; Edmond J LaVoie
Journal:  Bioorg Med Chem       Date:  2019-06-04       Impact factor: 3.641

Review 2.  Microbial efflux pump inhibition: tactics and strategies.

Authors:  George P Tegos; Mark Haynes; J Jacob Strouse; Mohiuddin Md T Khan; Cristian G Bologa; Tudor I Oprea; Larry A Sklar
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

3.  Multidrug resistance-selective antiproliferative activity of Piper amide alkaloids and synthetic analogues.

Authors:  Yue-Hu Wang; Masuo Goto; Li-Ting Wang; Kan-Yen Hsieh; Susan L Morris-Natschke; Gui-Hua Tang; Chun-Lin Long; Kuo-Hsiung Lee
Journal:  Bioorg Med Chem Lett       Date:  2014-09-06       Impact factor: 2.823

4.  Bioenhancers: Revolutionary concept to market.

Authors:  Navin Atal; K L Bedi
Journal:  J Ayurveda Integr Med       Date:  2010-04

5.  Antimicrobial and efflux pump inhibitory activity of caffeoylquinic acids from Artemisia absinthium against gram-positive pathogenic bacteria.

Authors:  Yiannis C Fiamegos; Panagiotis L Kastritis; Vassiliki Exarchou; Haley Han; Alexandre M J J Bonvin; Jacques Vervoort; Kim Lewis; Michael R Hamblin; George P Tegos
Journal:  PLoS One       Date:  2011-04-04       Impact factor: 3.240

Review 6.  Challenges and future prospects of antibiotic therapy: from peptides to phages utilization.

Authors:  Santi M Mandal; Anupam Roy; Ananta K Ghosh; Tapas K Hazra; Amit Basak; Octavio L Franco
Journal:  Front Pharmacol       Date:  2014-05-13       Impact factor: 5.810

7.  pH Modulation of efflux pump activity of multi-drug resistant Escherichia coli: protection during its passage and eventual colonization of the colon.

Authors:  Ana Martins; Gabriella Spengler; Liliana Rodrigues; Miguel Viveiros; Jorge Ramos; Marta Martins; Isabel Couto; Séamus Fanning; Jean-Marie Pagès; Jean Michel Bolla; Joseph Molnar; Leonard Amaral
Journal:  PLoS One       Date:  2009-08-17       Impact factor: 3.240

Review 8.  Recent Advances in Multi-Drug Resistance (MDR) Efflux Pump Inhibitors of Gram-Positive Bacteria S. aureus.

Authors:  Jadwiga Handzlik; Anna Matys; Katarzyna Kieć-Kononowicz
Journal:  Antibiotics (Basel)       Date:  2013-02-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.